Onkologie. 2020:14(3):122-125 | DOI: 10.36290/xon.2020.024

Circulating tumour DNA in patients with Hodgkin lymphoma

Alexandra Kredátusová1, Veronika Hanáčková2, Marie Lukášová2, Helena Urbánková2, Vít Procházka2
1 Lékařská fakulta Univerzity Palackého, Olomouc
2 Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc

Circulating tumour DNA (ctDNA) is extracellular DNA which can be found in peripheral blood of patients suffering from malignancies. A liquid biopsy as a method of its non-invasive assessment might be potentially useful in clinical practice especially in cases when there is no available source of tumour DNA for genotyping or when a sampling could be problematic due to technical issues or a patient´s condition. Quantitative and qualitative analysis of ctDNA might improve diagnostics and management of a disease and contribute to more personalised healthcare. It can be used in diagnostic screening for mutations, during therapy and at the end of treatment hand in hand with PET/CT imaging, as well as during follow-up. Better understanding of clonal evolution might help to identify patients resistant to checkpoint blockade.

Keywords: Hodgkin lymphoma, liquid biopsy, circulating tumour DNA.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kredátusová A, Hanáčková V, Lukášová M, Urbánková H, Procházka V. Circulating tumour DNA in patients with Hodgkin lymphoma. Onkologie. 2020;14(3):122-125. doi: 10.36290/xon.2020.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bachy E, Houot R. Hématologie. Paris: Ellipses Édition Marketing S.A. 2018: 352 s.
    2. Li M, Jia Y, Xu J, et al. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience. Ann Hematol. 2017; 96(8): 1343-1351. Go to original source... Go to PubMed...
    3. Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol. 2009; 20(8): 1408-1413. Go to original source... Go to PubMed...
    4. Vandenberghe P, Wlodarska I, Tousseyn T, et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2015; 2(2): 55-65. Go to original source... Go to PubMed...
    5. Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018; 131(22): 2413-2425. Go to original source... Go to PubMed...
    6. Desch A, Hartung K, Botzen A, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia 2020; 34(1): 151-166. Go to original source... Go to PubMed...
    7. Rossi D, Spina V, Bruscaggin A, et al. Liquid biopsy in lymphoma. Haematologica 2019; 104(4): 648-652. Go to original source... Go to PubMed...
    8. Baus D, Nonnenmacher F, Jankowski S, et al. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 2009; 23(10): 1885-1893. Go to original source... Go to PubMed...
    9. Roemer MG, Redd RA, Cader FZ, et al. Major Histocompatibilty Complex Class II and programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018; 36(10): 942-950. Go to original source... Go to PubMed...
    10. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016; 34(23): 2690-2697. Go to original source... Go to PubMed...
    11. Ansell SM, Lesokhin AM, Borello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015; 372(4): 311-319. Go to original source... Go to PubMed...
    12. Khurana A, Armand P, Ansell SM. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. Leuk Lymphoma. 2020; 8: 1-12. Go to original source... Go to PubMed...
    13. Di Trani M, Rizzo E, Locatelli S, et al. Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood 2019; 134(Suppl. 1): 131. Go to original source...
    14. Prochazka V, Henzlova L, Lukasova M, et al. Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision? Blood 2018; 132(Suppl. 1): 2933. Go to original source...
    15. Cirillo M, Borchmann S. An update on disease biomarkers for Hodgkin lymphoma.
    16. Sickinger MT, von Tresckow B, Kobe C, et al. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma - a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016; 101: 86-92. Go to original source... Go to PubMed...
    17. Camus V, Stamatoullas A, Mareschal S, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 2016; 101(9): 1094-101. Go to original source... Go to PubMed...
    18. Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on fuctional radiographic markers at presentation. Blood 2018; 131(1): 84-94. Go to original source... Go to PubMed...
    19. Procházka V, Gawande RS, Cayci Z, et al. Positron Emission Tomography-based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2018; 24(1): 64-70. Go to original source... Go to PubMed...
    20. Rossi D, Kurtz DM, Roschewski M, et al. The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA. Hematol Oncol. 2020; 38(1): 34-37. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.